We are live on ! Find out more

Adaptive Biotechnologies

ADPT

Market cap $4.05B

25.38 USD

-1.06

4.01%

At close Updated Aug 28, 2:46 PM EDT

1 day

-4.01%

5 days

-1.63%

1 month

12.7%

3 months

67.08%

6 months

57.44%

Year to date

59.52%

1 year

90.68%

5 years

-29.09%

10 years

-37.02%

About: Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Employees: 624

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 36.4%

Neutral 54.5%

Negative 9.1%

Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science

Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode

Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science

Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder

Adaptive Biotechnologies (ADPT) is transitioning to a pure-play MRD diagnostics company, with the spin-off of Immune Medicine revealing strong underlying profitability. MRD revenue grew 49% year-over-year (excluding milestones), sequencing gross margins exceeded 70%, and adjusted EBITDA margin reached 14%, supporting a high-growth, high-quality earnings profile. Refinancing eliminated a 5% perpetual revenue burden, while the planned separation of Immune Medicine should clarify earnings and remove $6M in quarterly adjusted EBITDA losses.

Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder

Zacks Investment Research

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript

Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript

Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago.

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies Q2 Earnings Call Highlights

Adaptive Biotechnologies NASDAQ: ADPT reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year revenue outlook. The company also outlined further steps toward separating its Immune Medicine operation and strengthened its balance sheet through a $340 million convertible note offering.

Adaptive Biotechnologies Q2 Earnings Call Highlights

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2026.

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

Zacks Investment Research

Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks Investment Research

Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock?

Adaptive Biotechnologies (ADPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock?

See News Rankings

Price charts implemented using Lightweight Charts™